IL152891A0 - Methods for decreasing cell proliferation based on (3r, 4r)-8-delta tetrahydrocannabinol-11-oic acids - Google Patents

Methods for decreasing cell proliferation based on (3r, 4r)-8-delta tetrahydrocannabinol-11-oic acids

Info

Publication number
IL152891A0
IL152891A0 IL15289101A IL15289101A IL152891A0 IL 152891 A0 IL152891 A0 IL 152891A0 IL 15289101 A IL15289101 A IL 15289101A IL 15289101 A IL15289101 A IL 15289101A IL 152891 A0 IL152891 A0 IL 152891A0
Authority
IL
Israel
Prior art keywords
tetrahydrocannabinol
cell proliferation
delta
methods
decreasing cell
Prior art date
Application number
IL15289101A
Other languages
English (en)
Original Assignee
Atlantic Technology Ventures I
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atlantic Technology Ventures I filed Critical Atlantic Technology Ventures I
Publication of IL152891A0 publication Critical patent/IL152891A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyrane Compounds (AREA)
IL15289101A 2000-05-17 2001-05-17 Methods for decreasing cell proliferation based on (3r, 4r)-8-delta tetrahydrocannabinol-11-oic acids IL152891A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20493500P 2000-05-17 2000-05-17
PCT/US2001/015916 WO2001087295A1 (en) 2000-05-17 2001-05-17 Methods for decreasing cell proliferation based on (3r, 4r)-δ8-tetrahydrocannabinol-11-oic acids

Publications (1)

Publication Number Publication Date
IL152891A0 true IL152891A0 (en) 2003-06-24

Family

ID=22760084

Family Applications (3)

Application Number Title Priority Date Filing Date
IL15289201A IL152892A0 (en) 2000-05-17 2001-05-17 Cannabinoid drugs
IL15289101A IL152891A0 (en) 2000-05-17 2001-05-17 Methods for decreasing cell proliferation based on (3r, 4r)-8-delta tetrahydrocannabinol-11-oic acids
IL152892A IL152892A (en) 2000-05-17 2002-11-17 Use of cannabinoids for the preparation of drugs for the treatment or prevention of cell culture diseases

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL15289201A IL152892A0 (en) 2000-05-17 2001-05-17 Cannabinoid drugs

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL152892A IL152892A (en) 2000-05-17 2002-11-17 Use of cannabinoids for the preparation of drugs for the treatment or prevention of cell culture diseases

Country Status (13)

Country Link
US (2) US6448288B1 (enExample)
EP (2) EP1307186A4 (enExample)
JP (2) JP2003533479A (enExample)
CN (2) CN1273123C (enExample)
AT (1) ATE406156T1 (enExample)
AU (5) AU2001264680B2 (enExample)
CA (2) CA2408961A1 (enExample)
DE (1) DE60135557D1 (enExample)
HU (2) HUP0700039A2 (enExample)
IL (3) IL152892A0 (enExample)
NZ (2) NZ523029A (enExample)
RU (2) RU2273476C2 (enExample)
WO (3) WO2001087296A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003075917A1 (en) 2002-03-08 2003-09-18 Signal Pharmaceuticals, Inc. Combination therapy for treating, preventing or managing proliferative disorders and cancers
WO2004103410A1 (en) 2002-06-06 2004-12-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods compositions and articles of manufacture for modulating bone growth
AU2003303376A1 (en) * 2002-12-19 2004-07-22 University Of Massachusetts Cannabinoid analogs as peroxisome proliferator activated nuclear receptor gamma activators
ATE496901T1 (de) * 2003-05-20 2011-02-15 Univ Tennessee Res Foundation Cannabinoidderivate, verfahren zu deren herstellung und deren verwendung
US20050070718A1 (en) 2003-09-30 2005-03-31 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
US8580842B2 (en) 2003-09-30 2013-11-12 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
GB2418612A (en) * 2004-10-01 2006-04-05 Gw Pharma Ltd Inhibition of tumour cell migration with cannabinoids
WO2006065792A2 (en) * 2004-12-13 2006-06-22 Indevus Pharmaceuticals, Inc. Treatment of interstitial cystitis using cannabinoid analogs
US20060128794A1 (en) 2004-12-13 2006-06-15 Indevus Pharmaceuticals, Inc. Treatment of interstitial cystitis using (6aR,10aR)-delta8-tetrahydrocannabinol-11-OIC acids
US20070037873A1 (en) * 2005-08-08 2007-02-15 Zurier Robert B Airway remodeling treatments
US7597910B2 (en) * 2005-08-20 2009-10-06 Slgm Medical Research Institute Compositions and methods for treating prostate disorders
CN101316832A (zh) 2005-09-29 2008-12-03 Amr科技公司 δ-9-四氢大麻酚的生成方法
US20070093519A1 (en) * 2005-10-20 2007-04-26 Indevus Pharmaceuticals, Inc. Anti-emetic uses of cannabinoid analogs
US20070099988A1 (en) * 2005-10-31 2007-05-03 Indevus Pharmaceuticals, Inc. Anti-emetic uses of (3r, 4r)-delta8-tetrahydrocannabinol-11-oic acids
US8486979B2 (en) 2006-12-12 2013-07-16 Abbvie Inc. 1,2,4 oxadiazole compounds and methods of use thereof
US20080167286A1 (en) 2006-12-12 2008-07-10 Abbott Laboratories Pharmaceutical compositions and their methods of use
UY30846A1 (es) 2006-12-30 2008-07-31 Abbott Gmbh & Amp Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
US7781650B2 (en) * 2007-04-30 2010-08-24 Monsanto Technology Llc Plants and seeds of corn variety CV202909
WO2008144475A1 (en) 2007-05-17 2008-11-27 California Pacific Medical Center Methods and compositions for treating cancer
WO2010009775A1 (de) 2007-12-07 2010-01-28 Abbott Gmbh & Co. Kg Carbamat-substituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen
JP5701607B2 (ja) 2007-12-07 2015-04-15 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー アミドメチル置換オキシインドール誘導体およびバソプレッシン依存性疾患の治療へのこれらの使用
US9023854B2 (en) 2007-12-07 2015-05-05 AbbVie Deutschland GmbH & Co. KG 5-halogen-substituted oxindole derivatives and use thereof for treating vasopressin-dependent diseases
JP5645217B2 (ja) 2007-12-07 2014-12-24 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー ５，６−二置換オキシンドール誘導体およびバソプレッシン依存性疾患を治療するためのこれらの使用
GB2471987B (en) 2008-06-04 2012-02-22 Gw Pharma Ltd Anti-tumoural effects of cannabinoid combinations
EP2435080A2 (en) 2009-05-29 2012-04-04 Abbott Laboratories Pharmaceutical compositions for the treatment of pain
GB2478595B (en) 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
GB2487712B (en) 2011-01-04 2015-10-28 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
GB2514054A (en) 2011-09-29 2014-11-12 Gw Pharma Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
GB2516814B (en) 2013-06-19 2016-08-31 Otsuka Pharma Co Ltd Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer
MA49772A (fr) 2017-08-04 2021-04-21 Merck Sharp & Dohme Agonistes benzo[b]thiophène de sting pour le traitement du cancer
WO2019027857A1 (en) 2017-08-04 2019-02-07 Merck Sharp & Dohme Corp. COMBINATIONS OF PD-1 ANTAGONISTS AND STING BENZO [B] THIOPHENIC AGONISTS FOR THE TREATMENT OF CANCER
CN111233814A (zh) * 2020-03-02 2020-06-05 福建省中科生物股份有限公司 一种萜酚类化合物zkyy-057及其制备方法和应用
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5A (en) * 1836-08-10 Thomas Blanchard Machine for mortising solid wooden shells of ships' tackle-blocks
US4327028A (en) * 1978-08-17 1982-04-27 Calcol, Inc. Composition of matter
ZA885929B (en) * 1987-08-25 1989-04-26 Oxi Gene Inc Agents for use in tumor or cancer cell killing therapy
US4973603A (en) * 1988-06-16 1990-11-27 Sumner Burstein Platelet activating factor antagonist and methods of use therefor
US4880030A (en) * 1988-07-25 1989-11-14 Terry Paul E Safety flow control fluid shutoff device
US5635530A (en) * 1991-09-12 1997-06-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem (3S,4S)-delta-6-tetrahydrocannabinol-7-oic acids and derivatives thereof, processors for their preparation and pharmaceutical compositions containing them
US5538993A (en) * 1991-09-12 1996-07-23 Yissum Research Development Company Certain tetrahydrocannabinol-7-oic acid derivatives
US5338753A (en) 1992-07-14 1994-08-16 Sumner H. Burstein (3R,4R)-Δ6 -tetrahydrocannabinol-7-oic acids useful as antiinflammatory agents and analgesics
US6162829A (en) * 1997-10-17 2000-12-19 Atlantic Pharmaceuticals, Inc. (3R,4R)-Δ8 -tetrahydrocannabinol-11-oic acids useful as antiinflammatory agents and analgesics
ES1045342Y (es) * 2000-02-11 2001-02-16 Alvarez Manuel Couto Expositor giratorio para postales, fotos y similares.

Also Published As

Publication number Publication date
DE60135557D1 (de) 2008-10-09
WO2001087295A8 (en) 2003-04-10
WO2001087296A1 (en) 2001-11-22
AU2001261695B2 (en) 2005-06-16
EP1307186A1 (en) 2003-05-07
WO2001087297A1 (en) 2001-11-22
RU2273476C2 (ru) 2006-04-10
CN1227007C (zh) 2005-11-16
ATE406156T1 (de) 2008-09-15
EP1307186A4 (en) 2005-10-19
EP1307188A1 (en) 2003-05-07
AU2001264680B2 (en) 2006-09-14
US6914072B2 (en) 2005-07-05
US6448288B1 (en) 2002-09-10
NZ523029A (en) 2004-11-26
WO2001087295A1 (en) 2001-11-22
US20040225011A1 (en) 2004-11-11
AU6468001A (en) 2001-11-26
CA2408961A1 (en) 2001-11-22
NZ523028A (en) 2004-09-24
HUP0700038A2 (en) 2007-05-02
CA2409005A1 (en) 2001-11-22
AU2001263217A1 (en) 2001-11-26
US20020022653A1 (en) 2002-02-21
CN1273123C (zh) 2006-09-06
IL152892A0 (en) 2003-06-24
HUP0700039A2 (en) 2007-05-02
AU6169501A (en) 2001-11-26
IL152892A (en) 2010-06-30
JP2003533478A (ja) 2003-11-11
EP1307188B1 (en) 2008-08-27
EP1307188A4 (en) 2005-07-06
JP2003533479A (ja) 2003-11-11
CN1452485A (zh) 2003-10-29
RU2272620C2 (ru) 2006-03-27
CN1447685A (zh) 2003-10-08

Similar Documents

Publication Publication Date Title
AU6169501A (en) Methods for decreasing cell proliferation based on (3r, 4r)-delta8-tetrahydrocannabinol-11-oic acids
MXPA03006093A (es) Derivados de n(fenilsulfonil)glicina y su uso terapeutico.
AU2001273728A1 (en) Arrangement for connecting planar components
BRPI0411897A (pt) pirroldihidroisoquinolinas como inibidores de pde10
AU2002316074A1 (en) System for quantifying edema
AU2002211663A1 (en) Nf-$g(k)b inhibitors
MXPA05002489A (es) Composiciones para el cuidado personal basadas en alcohol ramificado.
AU2003212310A1 (en) (4,2-disubstituted-thiazol-5-yl)amine compounds as pde7 inhibitors
AU2001283161A1 (en) Pumping arrangement for fiber amplifiers
HUP0304079A3 (en) Carcass alignment system for carcass splitter
AU2002235298A1 (en) Hydroformed running board
AU2002331595A1 (en) Novel vasoconstrictor cannabinoid analogs
AU2001263786A1 (en) Purified proenzyme of dipeptidyl peptidase i (pro-dppi)
AU2002351021A1 (en) Kit for reducing aching caused by pde-v inhibitors
AU2001265759A1 (en) Method for the highly parallel analysis of polymorphisms
AU2002220346A1 (en) Method for determination of the fertility of mammals, in particular of man
AU2002243647A1 (en) Novel mesogens
AU2002242942A1 (en) 3-0-'alfa-l-rhamnopyranosyl- (1-2) -alpha-l-rhamnopyranosyl- (1-4) -3beta-d-glucopyranosyl!-25 (s) -spirost an-3beta-ol, process for its isolation, and its use as immunomodulator
AU2001268268A1 (en) Latin draw poker
AU2002315472A1 (en) Fluoropyrrolidines as dipeptidyl peptidase inhibitors
HK1065532A (en) Fluoropyrrolidines as dipeptidyl peptidase inhibitors
IL150609A0 (en) Polarizing beam splitter
TW506650U (en) Improved structure for splitter
AU2002250319A1 (en) Polarization combiner/splitter
TW428765U (en) Light guiding plate used for back-light system